Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

Seymour, JF; Byrd, JC; Ghia, P; Kater, AP; Chanan-Khan, A; Furman, RR; O&#39;Brien, S; Brown, JR; Munir, T; Mato, A; Stilgenbauer, S; Bajwa, N; Miranda, P; Higgins, K; John, E; de Borja, M; Jurczak, W; Woyach, JA

Author(s): Seymour, JF; Byrd, JC; Ghia, P; Kater, AP; Chanan-Khan, A; Furman, RR; O'Brien, S; Brown, JR; Munir, T; Mato, A; Stilgenbauer, S; Bajwa, N; Miranda, P; Higgins, K; John, E; de Borja, M; Jurczak, W; Woyach, JA;
Details: Publication Year 2023-08-24,Volume 142,Issue #8,Page 687-699
Journal Title: Blood
Publication Type: Research article
Abstract: ELEVATE-RR demonstrated noninferior progression-free survival and lower incidence of key adverse events (AEs) with acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia. We further characterize AEs of acalabrutinib and ibrutinib via post hoc analysis. Overall and exposure-adjusted incidence rate was assessed for common Bruton tyrosine kinase inhibitor-associated AEs and for selected events of clinical interest (ECIs). AE burden scores based on previously published methodology were calculated for AEs overall and selected ECIs. Safety analyses included 529 patients (acalabrutinib, n = 266; ibrutinib, n = 263). Among common AEs, incidences of any-grade diarrhea, arthralgia, urinary tract infection, back pain, muscle spasms, and dyspepsia were higher with ibrutinib, with 1.5- to 4.1-fold higher exposure-adjusted incidence rates. Incidences of headache and cough were higher with acalabrutinib, with 1.6- and 1.2-fold higher exposure-adjusted incidence rate, respectively. Among ECIs, incidences of any-grade atrial fibrillation/flutter, hypertension, and bleeding were higher with ibrutinib, as were exposure-adjusted incidence rates (2.0-, 2.8-, and 1.6-fold, respectively); incidences of cardiac events overall (the Medical Dictionary for Regulatory Activities system organ class) and infections were similar between arms. Rate of discontinuation because of AEs was lower for acalabrutinib (hazard ratio, 0.62; 95% confidence interval, 0.41-0.93). AE burden score was higher for ibrutinib vs acalabrutinib overall and for the ECIs atrial fibrillation/flutter, hypertension, and bleeding. A limitation of this analysis is its open-label study design, which may influence the reporting of more subjective AEs. Overall, event-based analyses and AE burden scores demonstrated higher AE burden overall and specifically for atrial fibrillation, hypertension, and hemorrhage with ibrutinib vs acalabrutinib. This trial was registered at www.clinicaltrials.gov as #NCT02477696.
Publisher: American Society of Hematology
Keywords: Humans; *Atrial Fibrillation/drug therapy; Hemorrhage/chemically induced; *Hypertension/drug therapy; *Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy; Protein Kinase Inhibitors/adverse effects
Department(s): Clinical Haematology
PubMed ID: 37390310
Publisher's Version: https://doi.org/10.1182/blood.2022018818
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-11-14 12:41:53

Last Modified: 2023-11-14 12:43:26